Abstract
Treatment of locally advanced rectal cancer with multimodal treatment courses can result in significant morbidity. Nonoperative management is feasible for patients with clinical complete response to neoadjuvant therapies. Several recent reports have evaluated the use of immunotherapy with checkpoint inhibition for patients with mismatch repair-deficient rectal and colon cancers, with striking results.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1373-1375 |
| Number of pages | 3 |
| Journal | Current oncology reports |
| Volume | 24 |
| Issue number | 11 |
| DOIs | |
| State | Published - Nov 2022 |
ASJC Scopus subject areas
- Oncology